Skip to content
Menu

Reviva Pharmaceuticals Holdings, Inc. RVPH

Full chart Compare
Set alert

Price alert · RVPH

All alert types
0.28 USD 0.00 (-1.06%)

As ofNov 20, 2026, 3:57 PM EST

0.281 Day range 0.33495
0.281 52-week range 14.60
YTD
-94.96%
1 year
-97.07%

 

No chart data for this range yet.
Market cap
3.68M
EPS (ttm)
-0.39
Shares out
45.44M
Forward P/E
-2.02
YTD return
-94.96%
1-year return
-97.07%
50-day average
1.37
200-day average
1.70
Enterprise value
27.57M
Volume
5.46K
Avg volume
29.02K
Open
0.2905
Previous close
0.284
Day's range
0.281 – 0.33495
52-week range
0.281 – 14.60
Beta
-0.06
Analysts
Buy
Price target
14.80 (+5166.9%)

Key statistics

Price / book
8.00
Free cash flow
-17.42M
Total cash
6.18M
Total debt
207.50K
Short % of float
18.59%

Fundamental scorecard

5 of 25 checks passed on RVPH’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Mar 31, 2026.

Financials — quick view

All financials
RVPH Revenue — quarterly 0
RVPH Net income — quarterly -3.20M
RVPH EPS — quarterly -0.46

Earnings

RVPH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.23-0.25-0.02-8.70%
Aug 14, 2024Jun 1, 2024-0.28-0.26+0.02+7.14%
Aug 14, 2024Jun 1, 2024-0.28———
May 14, 2024Mar 1, 2024-0.28-0.25+0.03+10.71%
May 14, 2024Mar 1, 2024-0.28———
Apr 15, 2024Dec 1, 20230.00———

Upgrades / downgrades

RVPH analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024D. Boral CapitalmainBuyBuy
Nov 13, 2024D. Boral CapitalmainBuyBuy
Sep 23, 2024EF Huttoninit—Buy
Aug 26, 2024BenchmarkreitSpeculative BuySpeculative Buy
Aug 16, 2024Maxim GroupdownBuyHold
Jul 11, 2024HC Wainwright & Co.reitBuyBuy

About Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on RVPH — it syncs with the Stock Master app.

Institution ownership

RVPH institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC9.53%3,186,0005.23MSep 29, 2024
Millennium Management Llc5.48%1,832,8143.01MSep 29, 2024
Schonfeld Strategic Advisors Llc4.53%1,515,9002.49MSep 29, 2024
Vanguard Group Inc3.07%1,025,2491.68MSep 29, 2024
Woodline Partners LP2.05%684,8051.12MSep 29, 2024
Parkman Healthcare Partners LLC1.53%512,202840.01KSep 29, 2024

Fund ownership

RVPH fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.09%700,4421.15MSep 29, 2024
Vanguard Extended Market Index Fund0.93%312,304512.18KSep 29, 2024
Fidelity Extended Market Index Fund0.44%146,870240.87KOct 30, 2024
iShares Micro Cap ETF0.16%51,98485.25KOct 30, 2024
Fidelity Total Market Index Fund0.14%47,13977.31KOct 30, 2024
Fidelity Series Total Market Index Fund0.10%34,75957.00KOct 30, 2024